TL;DR
This study reveals a novel mechanism by which Helicobacter pylori infection exacerbates fatty liver disease (MASLD). The bacteria trigger lactate accumulation, which then leads to the lactylation and subsequent upregulation of the RNA-modifying protein WTAP. This WTAP-driven process promotes lipid accumulation in the liver by stabilizing the mRNA of the glucose transporter GLUT3, creating a vicious cycle that worsens steatosis.
What Problem Does This Paper Address?
Metabolic dysfunction-associated fatty liver disease (MASLD) is a growing global health concern, affecting a significant portion of the adult population. While Helicobacter pylori (H. pylori) infection has been linked to an increased risk of MASLD, the precise molecular mechanisms driving this connection have remained unclear. This paper aims to bridge this knowledge gap by investigating how H. pylori infection contributes to the development and progression of hepatic steatosis, focusing on the role of RNA modification and its potential link to bacterial infection.
Methods
The researchers employed a multi-pronged approach combining in vitro and in vivo models:
- In vivo studies: High-fat diet (HFD)-fed mice were infected with H. pylori to model MASLD. They also used lentivirus-mediated gene delivery (AAV8) to overexpress or knock down WTAP in mouse livers.
- In vitro studies: HepG2 cells were used to study the effects of H. pylori outer membrane vesicles (OMVs) and lactate on cellular processes.
- Molecular Biology Techniques:
- RNA Modification Analysis: Dot blot assays and MeRIP-qPCR were used to quantify global m<sup>6</sup>A levels and specific m<sup>6</sup>A modifications.
- Gene Expression Analysis: RT-qPCR and Western blotting were used to measure mRNA and protein levels of key genes and proteins, including WTAP, GLUT3, and metabolic pathway enzymes.
- Histology and Imaging: H&E, Masson, and Oil Red O staining were used to assess liver tissue morphology, fibrosis, and lipid deposition. Immunofluorescence microscopy was used to visualize protein localization and cellular structures.
- Post-Translational Modification Analysis: ChIP-qPCR was used to investigate histone lactylation, and LC-MS/MS was employed to identify specific lactylation sites on WTAP.
- Metabolomics: Untargeted metabolomics analysis was performed on liver tissues to identify metabolic changes.
- Molecular Docking: Used to predict the binding affinity between lactate and WTAP.
- Luciferase Reporter Assays: Used to assess the regulatory role of WTAP on GLUT3 mRNA.
- RNA Decay Assays: Used to determine the stability of GLUT3 mRNA.
Datasets
- Publicly Available Datasets: GEO public dataset (GSE260666) was used to analyze WTAP expression in MASH patients and the association between WTAP and lactate dehydrogenase.
- Newly Generated Data: RNA-seq and MeRIP-Seq data from the study were deposited in NCBI under SRA accession numbers (GSE301711).
Key Insights and Ideas
- H. pylori infection is a direct driver of hepatic steatosis: The study provides strong evidence that H. pylori infection exacerbates MASLD, leading to increased lipid deposition and insulin resistance.
- Lactate is a key mediator: H. pylori infection leads to increased lactate production in the liver. This lactate then acts as a signaling molecule.
- Lactylation of WTAP is a novel regulatory mechanism: Lactate directly induces lactylation of the WTAP protein, specifically at lysine residues K99 and K134. This lactylation enhances WTAP's stability and its ability to bind m<sup>6</sup>A-modified RNA.
- WTAP is a critical player in H. pylori-induced steatosis: Upregulation of WTAP, driven by lactylation, is essential for the exacerbation of hepatic steatosis. Knockdown of WTAP mitigates these effects.
- WTAP-YTHDF1-GLUT3 axis is central: WTAP promotes the stability of GLUT3 mRNA in an m<sup>6</sup>A-dependent manner, with YTHDF1 acting as the m<sup>6</sup>A reader. This leads to increased GLUT3 expression, enhanced glycolysis, and further lactate accumulation, creating a positive feedback loop.
- Therapeutic potential: The WTAP-YTHDF1-GLUT3 axis presents a promising therapeutic target for MASLD.
Key Results
- H. pylori-infected HFD mice showed significantly increased body weight, liver index, and microvesicular steatosis compared to controls.
- H. pylori infection led to elevated serum ALT, AST, TG, TC, and LDL levels, and suppressed genes involved in fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS), while upregulating genes for de novo lipogenesis.
- H. pylori OMVs increased lipid droplet accumulation and dysregulated lipid metabolism in HepG2 cells.
- Global m<sup>6</sup>A levels were elevated in HepG2 cells treated with OMVs and in the livers of H. pylori-infected mice.
- WTAP expression was consistently upregulated in the liver after H. pylori infection, both in vitro and in vivo.
- Overexpression of WTAP promoted liver steatosis characteristics, while knockdown of WTAP mitigated them.
- Lactate treatment of HepG2 cells increased WTAP mRNA and protein expression.
- Histone H3K18 lactylation was observed in the promoter region of WTAP, suggesting transcriptional regulation.
- LC-MS/MS identified K99 and K134 as key lactylation sites on WTAP.
- Mutating these sites abolished WTAP's ability to promote lipid droplet accumulation and increased its protein instability.
- MeRIP-Seq identified GLUT3 as a key downstream target of WTAP, with increased m<sup>6</sup>A modification in its CDS and 3'UTR.
- WTAP enhanced GLUT3 mRNA stability and protein expression, leading to increased glucose uptake and glycolysis.
- H. pylori eradication in infected mice reversed hepatic steatosis and normalized metabolic parameters.
Limitations and Future Work
- Adenovirus-based WTAP disruption: The study primarily used adenovirus for WTAP disruption, and the authors suggest that using knockout mouse models would be more robust.
- Limited OMV proteomic analysis: The study did not perform comprehensive proteomic analysis of H. pylori-derived OMVs, which could limit further investigation into specific toxins.
- 2D vs. 3D mitochondrial imaging: The use of 2D imaging for mitochondria might not fully capture complex structural changes. Future work will involve 3D imaging.
- Short-term eradication study: While the eradication study showed rapid reversal, longer-term follow-up is needed to assess its impact on preventing or reversing advanced MASLD stages.
- Limited validation of WTAP-YTHDF1-GLUT3 axis in human NASH: The validation of this axis was primarily based on public datasets, and direct validation in human NASH samples from their cohort is planned.
- Future research directions: The authors plan to focus on quantifying WTAP lactylation levels and evaluating the activity of the WTAP-m<sup>6</sup>A-YTHDF1-GLUT3 axis in liver biopsies from MASLD patients, with and without H. pylori infection. They also suggest future studies to confirm the role of GLUT3 in vivo using inducible hepatocyte-specific GLUT3 knockout models.
Summary updated